Mejía TGE

Language: Spanish
References: 8
Page: 97-99
PDF size: 78.06 Kb.

Text Extraction

No abstract

REFERENCES

1. Torres L, Calderón E, Rey M. Fentanilo transdérmico: características farmacológicas y aplicación clínica. Rev Soc Esp Dolor 1999; 6: 121-131.

2. Kanikkannan N, Kandimalla K, Lamba S, Singh M. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Current Medicinal Chemistry 1999; 6: 593-608.

3. Torres L, Martínez J, Contreras D. Fentanilo TTS en España: 3 años de experiencia clínica en Unidades del Dolor. Rev Soc Esp Dolor 2002; 9: 217-228.

4. Plancarte R, Allende S, Reyes M, Cabrera O. Fentanilo transdérmico en dolor oncológico. Rev Inst Nat Cancerol 1997; 43: 123-129.

5. Jeal W, Benfield P. Transdermal fentanyl: A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-138.

6. Le Loet X, Pavelka K Richarz U. Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. BMC Musculoskeletal Disorders 2005; 6: 31-41.

7. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005; 30: 2484-2490.

8. Rodríguez J, Aldaya J, De la Torre P. Fentanilo transdérmico en el tratamiento a largo plazo del dolor crónico no oncológico. Rev Soc Esp Dolor 2001; 8: 3-10.